Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Preferred Stock Liabilities: 2014-2023

Historic Preferred Stock Liabilities for Cartesian Therapeutics (RNAC) over the last 3 years, with Dec 2023 value amounting to $296.9 million.

  • Cartesian Therapeutics' Preferred Stock Liabilities was N/A to $296.9 million in Q4 2023 from the same period last year, while for Dec 2023 it was $296.9 million, marking a year-over-year change of. This contributed to the annual value of $296.9 million for FY2023, which is N/A change from last year.
  • Per Cartesian Therapeutics' latest filing, its Preferred Stock Liabilities stood at $296.9 million for FY2023, which was up 115.92% from $137.5 million recorded in FY2015.
  • In the past 5 years, Cartesian Therapeutics' Preferred Stock Liabilities registered a high of $296.9 million during FY2023, and its lowest value of $296.9 million during FY2023.
  • For the 1-year period, Cartesian Therapeutics' Preferred Stock Liabilities averaged around $296.9 million, with its median value being $296.9 million (2023).